Trevi Therapeutics, Inc.
TRVI
$16.64
-$0.18-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.63% | 35.86% | 38.15% | 33.81% | 32.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.46% | 30.01% | -16.52% | -1.21% | 3.26% |
| Operating Income | -49.46% | -30.01% | 16.52% | 1.21% | -3.26% |
| Income Before Tax | -44.59% | -27.64% | 26.91% | 10.97% | 0.31% |
| Income Tax Expenses | 9.52% | -81.82% | -200.00% | 51.61% | -162.50% |
| Earnings from Continuing Operations | -44.68% | -27.58% | 27.15% | 10.87% | 0.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.68% | -27.58% | 27.15% | 10.87% | 0.41% |
| EBIT | -49.46% | -30.01% | 16.52% | 1.21% | -3.26% |
| EBITDA | -49.63% | -30.13% | 16.52% | 1.23% | -3.27% |
| EPS Basic | -22.22% | -3.07% | 46.89% | 37.80% | 26.35% |
| Normalized Basic EPS | -22.20% | -3.09% | 46.73% | 37.85% | 26.41% |
| EPS Diluted | -22.22% | -3.07% | 46.89% | 37.80% | 26.35% |
| Normalized Diluted EPS | -22.20% | -3.09% | 46.73% | 37.85% | 26.41% |
| Average Basic Shares Outstanding | 18.37% | 23.79% | 37.25% | 43.27% | 35.27% |
| Average Diluted Shares Outstanding | 18.37% | 23.79% | 37.25% | 43.27% | 35.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |